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Tumorigenesis can in principle result from many combinations of mutations, but only a few roughly equivalent sequences of
mutations, or “progression pathways,” seem to account for most human tumors. Phylogenetics provides a promising way to
identify common progression pathways and markers of those pathways. This approach, however, can be confounded by the high
heterogeneity within and between tumors, which makes it diﬃcult to identify conserved progression stages or organize them
into robust progression pathways. To tackle this problem, we previously developed methods for inferring progression stages from
heterogeneous tumor proﬁles through computational unmixing. In this paper, we develop a novel pipeline for building trees of
tumor evolution from the unmixed tumor data. The pipeline implements a statistical approach for identifying robust progression
markersfromunmixedtumordataandcallingthosemarkersininferredcellstates.Theresultisasetofphylogeneticcharactersand
their assignments in progression states to which we apply maximum parsimony phylogenetic inference to infer tumor progression
pathways. We demonstrate the full pipeline on simulated and real comparative genomic hybridization (CGH) data, validating its
eﬀectiveness and making novel predictions of major progression pathways and ancestral cell states in breast cancers.
1.Introduction
The application of genomic technologies to cancers has
revealed that patients with tumors that appear indistinguish-
able to the clinician may have completely diﬀerent causes at
themolecularlevel[1,2]resultinginverydiﬀerentprognoses
[3] and responses to possible treatments [4]. Nonetheless,
mosthumancancersseemtofollowarelativelysmallnumber
of progression pathways [1, 2, 5], each characterized by
an approximately equivalent sequence of mutations. This
observation is key to the success of targeted therapeutics,
a groundbreaking approach to cancer treatment in which
drugs are developed to treat speciﬁc molecular abnormalities
shared by large subgroups of patients [6]. By identifying
common progression pathways and characterizing their con-
servedfeatures,itishopedthatwecanﬁndnewsubgroupsof
patients who will respond to a common treatment, identify
the speciﬁc abnormalities that will provide eﬀective ther-
apeutic targets for those subgroups, and develop clinically
useful diagnostic tests to identify new patients in those
subgroups. There are considerable practical challenges to
each of these steps, however.
One of the signiﬁcant challenges to identifying and
characterizing progression pathways is the heterogeneity of
cancers both within and between patients [7]. Any two
patients, even with a common progression pathway, will
exhibitmanydiﬀerencesinthedetailsofthecausalmutations
along that pathway, as well as in the assortment of random
passenger mutations distinct to each patient that do not
contribute to their pathology [8]. Even within a single
patient, a tumor will generally be highly heterogeneous, with
genetically distinct cell populations corresponding to diﬀer-
ent stages along the progression of their tumor and possibly
even diﬀerent branches along those progression pathways2 Journal of Biomedicine and Biotechnology
within a single tumor [9]. This heterogeneity is problematic
for methods for proﬁling tumor states, since there is at
present no technology to determine the genetic states of
single cells at a genomic scale. Genome-wide methods for
tumor proﬁling—such as expression microarrays, RNA-
seq, or array comparative genomic hybridization (aCGH)—
necessarily mix contributions from many discrete cell types.
This mixing would be expected to result in a conﬂation
of distinct states along a progression pathway, obscuring
characteristics of individual subpopulations of cells and
hiding the discrete steps in progression that may provide
clinically valuable markers of early stages in progression
or important clues to major decision points in a tumor’s
evolution. This heterogeneity is particularly challenging to
phylogenetic approaches to inferring tumor progression
[10], which depend on our ability to at least approximately
identify discrete steps in tumor evolution and can beneﬁt
greatly from information about ancestral states and the
combinations of states present in distinct tumor samples
[11].
There are various ways to approach the problem of
heterogeneity in tumor phylogeny inference. One approach
is to use alternative technologies designed to proﬁle single
cells as a way of directly observing discrete states within
tumors. This approach has been successfully used for
tumor phylogeny inference from single cell ﬂuorescent in
situ hybridization (FISH) data [12, 13]. Using single-cell
assays has substantial drawbacks, however, because single-
cell technologies can proﬁle only a few preselected markers
per cell. An alternative is to separate cells into approximately
homogeneous populations prior to applying genomic meth-
ods, aswasdone recentlyby[14], whoused a combination of
microdissection and post-dissection cell sorting to separate
discrete sub-populations of cells prior to whole-genome
DNA copy number proﬁling by aCGH. A third alternative,
used in the present work, is to apply genomic technologies
to heterogeneous samples but attempt to computationally
separate distinct cell populations from the outputs of these
samples. Such computational unmixing methods have been
previously used in tumor analysis to correct for stromal
contamination of tumor cells [15] and have been useful to
similarapplicationsofevolutionaryinferencefromheteroge-
neous samples, such as in reconstructing evolutionary steps
in viral quasispecies [16].
In previous work, we proposed the use of such unmixing
methods for identifying cell states for phylogeny inference
[11] and demonstrated their ability to separate biologi-
cally meaningful tumor cell populations from expression
microarray data [11] and aCGH data [17]. In this paper,
we build on that prior work by developing a pipeline
for converting inferred cell proﬁles into phylogenetic trees
describing likely stages of tumor progression and common
progression pathways by which they evolve. This pipeline
implements four distinct steps. The ﬁrst applies our prior
unmixing model [17] to infer proﬁles of major progression
steps from heterogeneous tumor data. The second step uses
a novel statistical test to identify ampliﬁed genomic regions
that can serve as markers of progression. The third step then
uses a second statistical approach to call these markers as
ampliﬁed or nonampliﬁed in individual inferred cell states,
creatingamatrixofphylogeneticstatessuitableforcharacter-
based phylogenetic inference. The fourth step then applies
maximum parsimony phylogeny inference to the resulting
data to identify likely progression trees, labeled by changes in
the marker set inferred in step two. These progression trees
establish a model of tumor evolution identifying discrete
steps of progression among these markers and possible
ancestral stages of tumor progression not directly apparent
from the identiﬁed components. Validation on simulated
data demonstrates the eﬀectiveness of the method at iden-
tifying markers, assigning them to progression states, and
inferring trees from those states. Application to real breast
cancerCGHdataresultsinaphylogenythatrecapitulateskey
features of our current understanding of major breast cancer
progression pathways while elaborating in several potentially
signiﬁcant ways. The work represents, to our knowledge, the
ﬁrst use of character-based phylogenetic inference for similar
whole-genome tumor proﬁles, providing advantages over
priordistance-basedapproachesinidentifyinglikelymarkers
anddescribingspeciﬁcmutationsthatmayunderliekeysteps
in tumor progression.
In the remainder of this paper, we present our method
and an application to a publicly available aCGH data set. In
Section 2.1, we describe our overall phylogenetic inference
pipelineandthenovelcomputationalandstatisticalmethods
developed for it. In Section 2.2, we provide details on speciﬁc
use of the methods developed here and their application
to the analysis of the breast tumor aCGH data of [14]. In
Section 3, we present the results, identifying a set of phyloge-
netic markers and a resulting tumor phylogeny. In Section 3,
we also discuss the biological signiﬁcance of the results,
examining both their concordance with prior literature and
interesting novel predictions of the methods. Finally, in
Section 4, we consider avenues for future work.
2.MaterialsandMethods
2.1. Algorithms. At a high level, our method consists of
an analysis pipeline to convert raw data on proﬁles of
heterogeneous tumor samples into phylogenetic inferences
on computationally inferred proﬁles of discrete cell states.
While the method can in principle work with any technology
for proﬁling tumor state, we assume in the present work that
we are speciﬁcally using aCGH data describing DNA copy
n u m b e r sa tad i s c r e t eg e n o m e - w i d ep r o b es e t .T h ed a t aa r e
assumed to be in the form of copy numbers of n probes
in m tumors or tumor sections. These data are assumed to
be raw or baseline normalized raw input, rather than the
conventional log ratios.
The overall analysis pipeline is summarized in Figure 1.
The pipeline consists of the following steps:
(1) computational unmixing of raw aCGH data to infer
aCGH proﬁles of well-populated tumor states,
(2) identiﬁcation of signiﬁcantly ampliﬁed marker
regions of the genome from the component aCGH
data,
(3) assignment of marker states to components,Journal of Biomedicine and Biotechnology 3
Mixture Signiﬁcant  Marker 
Unmixing Marker Phylogeny 
Whole
genome
data
components marker set state set
Tumor 
progression
tree
selection
Marker state
assignment construction
Figure 1: Workﬂow diagram summarizing the major steps in our unmixing-based phylogenetic analysis pipeline.
(4) phylogenetic inference on cell states to produce an
inferred progression tree.
The individual steps of this analysis are as described below.
2.1.1. Unmixing Analysis. Our phylogenetic approach
assumes data that has been separated into mixture compo-
nents. We initially accomplished this assignment using an
unmixing method previously developed by our group [17]
based on an interpretation of the problem as that of ﬁtting
a simplex to an observed set of data points, where simplex
vertices will then correspond to inferred components of the
mixture. The method is based on prior work by Ehrlich
and Full [18] adapted to better handle the high dimension
and noise level characteristic of genomic data. We have
since updated that method to use nonnegative matrix
factorization (NNMF) [19] to eliminate the possibility of
negative copy number values and other artifacts that can
induce in the code.
Figure 2 illustrates the unmixing procedure. We ﬁrst pre-
process the data by applying L1-L1 total variation denoising
to the raw aCGH proﬁles. In the initial method, we then
use principal components analysis (PCA) to convert aCGH
proﬁles of tumor samples to points in a low-dimensional
space. The aCGH proﬁles are then explained as mixtures
drawn from a set of common cell types by ﬁtting a simplex
to the point set, with some allowance for noise in the
data. Any point in the simplex can then be explained as
a linear combination of the vertices of the simplex. These
vertex points are interpreted as the cell types from which
each tumor sample is generated and can be projected back
into the original dimension of the aCGH array to construct
virtual aCGH proﬁles of the inferred cell types. The outputs
of the method are an inferred set of mixture components,
identifying a projected copy number of each cell type at
each probe, and a set of mixture fractions, explaining each
observed tumor sample as a sum of fractional contributions
of cell types. The mixture components can be represented
as a matrix C in which each entry cij describes the inferred
copy number of component or cell type i at aCGH probe
j. For the present pipeline, we use only the component
matrix C and discard the mixture fractions. Space does not
permit a detailed description of the method, so we refer the
reader to [11]foramorethoroughdescriptionofourgeneral
unmixing strategy for tumor phylogenetics and to [17]f o r
a detailed discussion of the speciﬁc noise-tolerant unmixing
algorithm used in our primary results here. Our most
recent algorithm functions identically except that initially
dimensionality reduction is accomplished by NNMF rather
than PCA and an additional nonnegativity constraint is
imposed during the optimization of components C.
The primary results below are based on components
previously determined in Tolliver et al. [17] by the PCA-
based method, although the improved method is applied
to develop components from simulated data and from a
secondary breast cancer data set to provide additional points
of comparison.
2.1.2. Identiﬁcation of Ampliﬁed Genomic Regions. Once we
have the inferred components, it is next necessary to identify
markers for tracking phylogenetic state. For aCGH data, we
seek genomic regions that are ampliﬁed in subsets of tumors.
We focus on ampliﬁcations due to a technical limitation
of the unmixing approach. Unmixing is performed in the
linear, rather than log, domain, and a deletion represents
only a small linear change in copy number, so we expect the
method to have poor sensitivity to deletions. Given the high
variability from probe to probe in the data, it is necessary to
use a statistically robust test for ampliﬁcation. To accomplish
this, we developed a test designed to test for signiﬁcant
ampliﬁcation of a window of w contiguous probes across the
m components.
We assume Gaussian noise in the data, thus modeling
each individual probe as drawn from a Gaussian distribution
with mean 1 (corresponding to diploid DNA). The variance
is assumed to be the empirically measured variance, σ2,
across all probes in all components. We then seek to reject
the hypothesis that the collection of w × m probes under
consideration were drawn from the corresponding Gaussian.
For this purpose, we take as our statistic the sum of squares
of Z-scores of the probe values:
Xk =
m 
i=1
k+w−1 
j=k
cij − 1
σ
2
,( 1 )
where k is the index of the ﬁrst probe in the window. Under
thenullhypothesis,thisstatisticwouldbeexpectedtobechi-
square distributed with w × m degrees of freedom. We thus
test for signiﬁcant ampliﬁcation with a one-sided chi-square
signiﬁcance test for the appropriate degrees of freedom.
We apply this test to sliding windows of probes of ﬁxed
width w across the genome. After identiﬁcation of discrete
ampliﬁed windows, we apply a postprocessing step to col-
lapse any overlapping ampliﬁed windows into a single larger
window and treated the union of probes in all overlapping
signiﬁcant windows as the marker for subsequent analysis.4 Journal of Biomedicine and Biotechnology
Figure 2: Illustration of the unmixing approach. Tumor samples T1–T4 are assayed by aCGH, generating genome-wide copy number
proﬁles. The aCGH proﬁles are interpreted as points in a space (two-dimensional in the example) and are unmixed by ﬁtting a simplex
to the point set (a 3-simplex, or triangle, in the example). The vertices of the simplex represent inferences of three cell types (1, 2, and 3)
from which T1–T4 can be explained. These vertices are then projected back to the dimension of the aCGH arrays to construct virtual aCGH
proﬁles of the inferred cell types. The outputs are these virtual aCGH proﬁles and the inferred fractional amount of each cell type in each
tumor sample.
We would normally expect the detected regions to be a
subset of those one would ﬁnd by performing a comparable
statistical test on the raw aCGH measurements rather than
the inferred components, as we would expect that features
that are not robust to a signiﬁcant fraction of samples will be
interpreted as noise and suppressed at the unmixing step.
The scan for signiﬁcant windows was done through
custom Matlab code using the chi2cdf function for chi-
square signiﬁcance testing.
2.1.3. Assignment of Marker States to Components. After
identifying a set of markers, we next need to determine the
states of those markers in each inferred cell component.
For this purpose, we again treat the problem as that of
attempting to reject the hypothesis that the individual copy
numbers are drawn from a Gaussian of mean 1 and variance
corresponding to the empirically measured variance across
all probes. For each component i and marker j,w ec o m p u t e
the mean copy number over all probes in the given marker
for the given component:
μij =
1
bj − aj +1
bj 
k=aj
cik,( 2 )
where aj is the leftmost probe index and bj the rightmost
probe index for marker j. We then evaluate the single-sided
P value for the hypothesis that μij is drawn from a Gaussian
with mean 1 and variance σ2/(bj −aj +1),whereσ2 is again
the empirical variance across all probes in all components.
We implicitly build in a prior probability that any given
marker is not ampliﬁed in any given component by using
a P value cutoﬀ of 0.001 for calling a probe ampliﬁed. The
result of this analysis is an assigned state (ampliﬁed or not
ampliﬁed) for each component at each phylogenetic marker.
T h e s ev a l u e sc a nb er e p r e s e n t e da sa nm +1× k matrix P
of phylogenetic markers, where element pij is a binary value
indicating whether marker j is ampliﬁed or not ampliﬁed in
component i.
Custom Matlab code was used to assign phylogenetic
states to each component at each marker using the normcdf
function.Journal of Biomedicine and Biotechnology 5
2.1.4. Phylogeny Construction. The matrix of phylogenetic
marker states P produced in the previous step serves as the
input to a character-based phylogenetic inference. Given the
lack of any sound empirical basis for setting parameters
for a Bayesian or maximum likelihood method, we favor
use of a simpler parsimony method and therefore treat
tumor phylogeny inference as the problem of ﬁnding a
maximum parsimonySteiner tree[20]inwhichtheobserved
components are leaves of the tree. For similar reasons, we
do not weight markers, treating gain or loss of any marker
as equally likely and seeking a minimum weight Steiner
tree capable of explaining the data. The actual phylogeny
construction is accomplished with PAUP [21]( P o r t a b l e
version 4.0b10 for Unix). The program was run with the
maximum parsimony optimality criterion using heuristic
search for 10 repetitions, random sequence addition, and the
tree bisection reconnection option for swapping. Trees were
visualized with GraphViz [22].
2.2. Computational Analysis
2.2.1. Simulated Data. As a ﬁrst validation, we applied our
methods to a set of simulated aCGH data to speciﬁcally
test the eﬀectiveness of our method at identifying markers,
grouping them into components, and properly placing the
components in a phylogenetic tree. We simulated data for a
single hypothetical chromosome of 1000 probes, assuming
cell states evolve according to a binary tree from an initially
diploid root state. We then assumed each of the edges would
contribute a single mutation, represented as a segment of 11
consecutive probes with ampliﬁcation level 20 placed uni-
formly at random on the simulated chromosome, rejecting
placements that would place segments less than 10 probes
away from another segment. We then drew 200 simulated
tumor samples from this tree of components by choosing
a single node at random from the tree and using all nodes
on the path from the root to chosen node as the mixture
components of that sample. We chose mixture fractions for
thecomponentsineachsimulatedtumorsamplebychoosing
uniform random weights for each component assigned to
the sample and normalizing by the sum of these weights to
derive fractional contributions of each component to each
mixturefraction.Finally,weaddsimulatedGaussiannoiseto
eachprobevalueforeachsimulatedtumorsamplewithmean
zero and standard deviation set to 0.05, 0.10, 0.15, and 0.20
in separate experiments. We then applied the NNMF-based
unmixing algorithm with regularization parameter 100 and
the analysis pipeline described above using a P value cutoﬀ
of 10−6 and window size of 5 for marker identiﬁcation.
We measured accuracy based on ampliﬁed segments
correctly identiﬁed, components correctly identiﬁed, and
tree edges correctly identiﬁed. We ﬁrst assessed the fraction
of the ampliﬁed segments correctly identiﬁed during marker
selection for each scenario. Next, we computed the fraction
of components correctly identiﬁed, with an assignment
judged correct if it was assigned the same state as the true
component for all markers that were correctly identiﬁed in
the previous step. Finally, we assessed the fraction of tree
edges correctly identiﬁed among those subdividing nodes
correctly identiﬁed in the previous step. A tree edge was
considered correct if it subdivided the node set identically
in the inferred tree and in the true tree when collapsed to
the subset of nodes identiﬁed correctly during the marker
assignment step. All three analyses were repeated for k = 4–7
components for each of the four noise levels.
2.2.2. Real Data. Our primary analysis consisted of applica-
tion of our method to a set of previously identiﬁed mixture
components derived in [17] using a publicly available set
of aCGH data from sectioned primary ductal breast tumors
[14].Thisdatasetwasselectedbecausethesectioningandcell
sorting approach developed by Navin et al. was speciﬁcally
chosentofacilitatephylogeneticinferenceandprovidesaddi-
tional data on intratumor heterogeneity useful in validating
the methods. The raw data comprises 87 tumor sectors
obtained from 14 ductal breast cancer tumors run on a high-
density ROMA platform with 83,055 probes. We conﬁned
our analysis to the twenty-two autosomal chromosomes,
reducing the dataset to 78,874 probes.
The raw aCGH data was preprocessed and unmixed
as described in our prior work [17]. As before, data was
converted from log to linear domain, denoised with a total
variation denoising, and unmixed to generate components.
Six components were chosen, as described in the prior work,
based on an analysis of the eigen-decomposition of the data.
The resulting components are the same as those described
in that prior paper and we refer the reader there for detailed
information on the unmixing method and its application to
this data set.
Phylogenetic markers were determined from the result-
ing component matrix as described in Approach. We used a
window size of w = 20 for the initial sliding-window scan
of the genome. The P value threshold for each window in
isolationwassetto10−8 toaccountforBonferronicorrection
for the 78,855 sliding windows of size 20 possible for the
78,874 probes. This threshold corresponds to a corrected P
value threshold of 7.9 × 10−4. After collapsing overlapping
windows,we found a total of 27 phylogenetic marker regions
signiﬁcantly ampliﬁed across samples. In order to investigate
the possible biological signiﬁcance of these markers, we
identiﬁed all genes overlapping the probe set for each marker
region using the UCSC Genome Browser [23] applied to the
human reference genome build 17 (NCBI35). We use NCBI
build 35, rather than a more recent build, to conform to
the aCGH platform speciﬁcations. We further attempted to
identify any genes with a known association with cancer by
manually examining Online Mendelian Inheritance in Man
(OMIM) [24] entries for all genes overlapping the probes,
speciﬁcallynotingthosewithapriorassociationwithcancers
in general or breast cancers speciﬁcally.
2.2.3.ApplicationtoanIndependentDataSet. Asasecondary
validation of our approach, we applied it to a second set
of mixture components derived from a second publicly
available second breast cancer aCGH dataset [25] consisting
of 44 predominantly advanced primary breast tumors and
10 breast cancer cell lines. The dataset consists of 59 samples
and6691probeseachcorrespondingtoasinglegene,making6 Journal of Biomedicine and Biotechnology
it substantially lower in resolution than the Navin et al.
dataset. We ran our recent NNMF-based unmixing method
withTVdenoisingregularizationparameter6and,unmixing
parameters k = 6 components and γ = 100 regularization,
with window size 20 and bonferroni corrected P-value cutoﬀ
1.7 × 10−7. While the lower resolution of the data prevented
directcomparisontotheNavinetal.results,weevaluatedthe
method based on its ability to identify four markers (on 1q,
8q, 17q and 20q) speciﬁcally cited by the authors of the study
as well as others that showed up as important markers in the
analysis of the Navin et al. data.
3. Results andDiscussion
3.1. Results
3.1.1. Simulated Data. Figure 3 summarizes results on the
simulated data. Surprisingly, marker-level accuracy generally
improves with increasing component numbers but appears
relatively insensitive to noise level over the ranges examined
here. The average accuracy across all scenarios is 79.2%. No
falsepositivemarkersweredetectedinanyofthesimulations.
Component-level accuracy shows a more complicated pro-
ﬁle, with generally worse performance for larger numbers
of components at any given noise level. Analysis of speciﬁc
identiﬁed components suggests a common error is the
identiﬁcation of more than one inferred component closely
corresponding to a single true component, leading to other
true components getting omitted from the data. The overall
average accuracy in component assignment is 72.8% over
all scenarios. The accuracy of tree edges in partitioning the
identiﬁed components is 100% across most noise levels and
component numbers, except for 20% noise and 15% noise
for k = 6 components and 20% noise for k = 7 components.
The overall accuracy in inferring tree edges is 94.8%. It
is important to note, though, that we deﬁned these error
measures so that the method would not be penalized for
failed marker detection in assessing component or tree edge
detection nor be penalized for failed component detection
in assessing tree edge detection. This decision was motivated
by a desire to assess the accuracy of each step independent
of the others. The reported accuracies would appear more
pessimistic if we counted components correct only if all
markers were detected or counted tree edges incorrect if the
components they separate were not detected.
3.1.2. Real Tumor Data. Application of our analysis to the
[14] data yielded six components corresponding to inferred
cell states, in addition to a seventh normal cell type added
to root the subsequent tree. The components themselves and
a detailed analysis of those components and the associated
mixturefractionsareprovidedinourpriorwork[17]andw e
thereforereferthereadertothatpriorliteratureforadetailed
discussion of the mixture components by themselves.
We next analyzed the components to ﬁnd signiﬁcantly
ampliﬁed marker regions. The analysis yielded a total
of 27 nonoverlapping regions at which the components
collectively showed signiﬁcant ampliﬁcation. The full set
of marker regions is provided in Table 1. In addition, we
providealistofgenesoverlappingtheregionsthathavesome
known association to cancers. Most of the regions contain
at least one gene known to have some prior association
with cancers, including several genes speciﬁcally associated
with breast cancers (CD55, MDM4, WNT2, ERBB2, GRB7,
BCAS, CCNE, CTTN, AURKA, BCL2, MYC, TNFRSF11A,
ZNF217, CYP24A1). In several other cases, a region lacking
known cancer-associated genes is found adjacent to one with
a known association and might be presumed to be part of a
common amplicon (e.g., 18q22.2-18q22.3).
These regions overlap a total of 343 genes, of which 56
(16.3%) were manually found to be associated with cancers
in OMIM. It is diﬃcult to rigorously establish a global
frequency with which genes are cancer related, but we can
derive an estimate by reference to the work Bajdik et al. [26],
who used a text-mining approach to determine that 1,943
genes as of the time of their work were annotated as cancer-
related in OMIM. Comparing this number to the number of
Refseqtranscripts,27,704(NCBIgenomebuild35),provides
an estimate that 7.01% of all genes are annotated as cancer-
associated in OMIM. The comparison suggests that the
marker regions identiﬁed by our study are strongly enriched
for known cancer-related genes. A chi-squared statistical test
shows this diﬀerence in frequencies to be highly signiﬁcant
(chi-square score 43.2, P value <0.0001).
We would expect the unmixing to screen out ampli-
ﬁcations that occur in only a small fraction of samples,
leading to the discovery of fewer but more robust markers
than would be found from the raw aCGH data. To test that
assumption, we also ran the marker selection method on
the raw aCGH data. This process yielded 47 marker regions,
including 24 of the 27 found from the unmixed data. Three
markers (Markers 6, 22, and 23) are found only from the
unmixed data. Due to space limitations, we do not provide
the complete list of markers obtained from the raw data.
We next assigned states to each of the identiﬁed marker
regions in each component. Table 2 shows the full assign-
ment of marker states to components. We further manu-
ally examined the copy number proﬁles for the predicted
components in each marker region. Figure 4 provides two
illustrativeexamples,showingtheinferredcopynumberdata
for the six components and identifying those components
determined to be ampliﬁed versus nonampliﬁed. Figure 4(a)
shows the inferred proﬁle for marker 1, corresponding to
locus 1q32.1-1q32.2. C1, C3, C4, and C5 are determined to
be ampliﬁed, which appears to provide a good correspon-
dence to those with copy numbers signiﬁcantly above one. It
is worth noting, however, that there is a ﬁner resolution of
ampliﬁcation apparent in the Figure 4(a): C1 shows broad
but low ampliﬁcation across the region, C3 shows a more
speciﬁc ampliﬁcation of the subregion approximately from
probes 5250 to 5300, and C4 shows a distinct pattern of
multiple amplicons across the region. These observations
suggest the marker-identiﬁcation method is performing well
at a coarse resolution but that there is considerable ﬁner-
scale structure that could in principle exploited by a more
sophisticated marker selection strategy, particularly where
contiguous regions show distinct patterns of ampliﬁcation.Journal of Biomedicine and Biotechnology 7
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Figure 3: Quantiﬁcation of accuracy on simulated data from k = 4–7 components and noise levels 0.05–0.20. (a) Fraction of markers
correctly predicted in each experiment. (b) Fraction of components correctly identiﬁed on all identiﬁed markers in each experiment. (c)
Fraction of tree edges correctly identiﬁed for the components and markers identiﬁed in each experiment.
Figure 4(b) shows a second example, the inferred copy
number proﬁle for marker 20, corresponding to an amplicon
at 17q12-17q21.2. We would expect this site to be picked
up as a marker and to show high ampliﬁcation, since it
is the site of the Her-2 locus. The region again shows a
strong but selective ampliﬁcation, with C5 and C6 highly
ampliﬁed (although with distinct ﬁne-scale structures), C4
slightly ampliﬁed, and others showing no ampliﬁcation.
The result again conﬁrms that the method produces correct
answers at a coarse resolution, although there may be a ﬁner-
scale structure that could exploited by a more sophisticated
method.
Using the resulting probes, we then performed phy-
logenetic inference. Figure 5 shows the phylogenetic tree
produced from the six inferred progression components and
the additional normal component manually added to the
analysis. The majority of markers are gained at a unique
point in the tree and never subsequently lost. Marker 9
(8q12.1) is lost in the tree in the transition to component
C4.Inaddition,somemarkersareinferredtobegainedmore
than once in the tree. Most notable of these is the collection
of 17q markers, which are gained separately in the subtree
leading to component 6 and that leading to Steiner node 8
and then to components 4 and 5.
3.1.3. Application to an Independent Data Set. Application to
a second component set derived from the lower-resolution
data of Pollack et al. [25] provides a secondary validation of
the reproducibility of the results on distinct datasets, aCGH
platforms, and unmixing methods for a common tumor
type. The method identiﬁed 20 markers, shown in Table 3.
The lower resolution of the data leads to substantially more
possible genes per amplicon than were found with the Navin
et al. data, making it infeasible to conduct a similar analysis
of the genes identiﬁed. We therefore must compare the two
results more indirectly based on markers reported by Pollack
et al. in their own analysis of their data as well as known
breast cancer markers found in the primary analysis of the
Navinetal.dataabove.Pollacketal.describedﬁnding1q,8q,
17q, and 20q as predominantly ampliﬁed regions in the data,
and our method did ﬁnd sizeable amplicons on each of these
regions. Other amplicons appear to correspond to several
important tumor markers, including the HER2, CCND1, c-
myc, and CCNE1 loci noted in the analysis of the Navin
et al. data as well as the FGFR1 locus that is conspicuously
absent from our analysis of the Navin et al. data. Of note, the
CCNE1locusisfoundasasigniﬁcantmarkerwhenanalyzing
the unmixed components but is not detected by a similar
marker analysis of the raw data without unmixing. All other8 Journal of Biomedicine and Biotechnology
Table 1: Marker regions determined to be signiﬁcantly ampliﬁed across components for the data of Navin et al. [14]. The table provides, for
each marker region, a unique identiﬁer, cytogenetic coordinates, probe positions along the genomic axis, and gene IDs for genes identiﬁed
as having some known association with cancers.
Marker ID Cytogenetic coordinates Chromosome positions Annotated cancer-related genes
1 1q32.1-1q32.2 196117366-206330147 CD55, MDM4, NR5A2,PTPN7,
IL10, CNTN2,CD34
2 1q44 242649493-245131380 SMYD3
3 2p12 76777788-78642108 None
4 3q25.1-3q25.2 151037467-154216571 None
5 5p15.33-5p14.2 3485419-24119655 PAPD7, TAG, CDH18
6 5q21.1-5q21.3 100224934-106834646 None
7 5q22.3-5q23.1 115172420-118711133 TNFAIP8, ATG12, SEMA6A
8 7q31.2-7q31.31 116016939-120372452 ING3,ASZ1, WNT2, ST7
9 8q12.1 55969808-58018737 None
10 8q12.3-8q13.2 63931435-69387571 MYBL1
11 8q13.2-8q13.3 69634776-74092165 TRPA1
12 8q21.11-8q24.3 77351432-143296089 MYC
13 11q13.2-11q13.4 67830873 -70354248 CCND1, CTTN, FGF4, FGF3
14 11q14.1-11q13.4 74383378-82935709 None
15 11q23.3 115171785-116542726 None
16 12p11.22-12p11.21 28901065-33207415 ERGIC2
17 15q25.2-15q25.3 82525637-85513682 None
18 15q26.3 96434691-99661839 None
19 17q11.2 23392447-25127504 RAB34, NEK8, TRAF4, FOXN1
20 17q12-17q21.2 32705491-37628927 STAT5, ERBB2, GRB7
21 17q21.33 45403785-47282174
SPAG9, UTP18, CA10,
ANKRD40, CACNA1G,
PPP1R9B
22 18q21.32-18q22.2 56806538-66527883
TNFRSF11A, BCL2, SERPINB5,
SERPINB13, SERPINB4,
SERPINB3, CDH19
23 18q22.2-18q22.3 66607283-71314138 None
24 19q12 34017456-36812510 CCNE1
25 20q13.12 44249187-45563781 None
26 20q13.2-20q13.32 50440150-57022263
ZNF217, CYP24A1, BCAS1,
AURKA, CTCFL, ZBP1,
RAB22A, GNAS, SDX16
27 20q13.33 57624055-58571221 None
markers found in the unmixed data are also found in the
raw data, as was observed with the Navin et al. data. Figure 6
shows the inferred phylogenetic tree. For these data, it was
not necessary to add a normal root component C0, as was
done with the Navin et al. data, because the method directly
inferred component C1 to be nonampliﬁed at all markers
and thus to serve as the expected normal root.
3.2. Discussion. Analysis on simulated data shows the
method to have generally good accuracy at identifying
ampliﬁed markers, identifying complete components with
deﬁnedpatternsofmarkerampliﬁcation,andgroupingthese
components into phylogenies. The dependence of accuracy
onvariousmodelparametersisdiﬃculttoanalyze,withgen-
erally better marker-level accuracy but worse component-
level and tree-edge-level accuracy as greater numbers of
components are modeled. Examination of diﬀerent noise
levels, chosen to roughly approximate noise levels observed
on the real data, shows no strong dependence within a range
of 5–20% noise. Overall, the results suggest that methods
show good although far from perfect performance, picking
out 79.2% of true markers and greater than 72.8% of true
components in most scenarios and correctly identifying
94.8% of tree edges dividing the identiﬁed components. The
high speciﬁcity of the marker assignment, with no false
positives observed in any of the tests, suggests that thereJournal of Biomedicine and Biotechnology 9
Table 2: Phylogenetic states of all components at all identiﬁed progression markers for the data of Navin et al. [14]. Columns show the states
for the six inferred components (C1–C6). The additional normal component (C0) used to root the tree is included for completeness. “1”
corresponds to an ampliﬁed region and “0” to nonampliﬁed.
Marker ID C0 C1 C2 C3 C4 C5 C6
1 0101110
2 0101110
3 0001000
4 0001000
5 0001110
6 0000101
7 0000101
8 0001000
9 0101010
1 0 0101110
1 1 0101110
1 2 0101110
1 3 0000110
1 4 0010100
1 5 0000001
1 6 0100100
1 7 0000100
1 8 0000101
1 9 0000111
2 0 0000111
2 1 0000111
2 2 0010000
2 3 0010000
2 4 0100001
2 5 0001110
2 6 0001110
2 7 0001110
may be room to tune the methods to improve accuracy by
trading oﬀ sensitivity for a somewhat higher rate of false
positives. While simulated data provides some assessment
of the eﬀectiveness of the method, however, there are many
features of tumor evolution that are not yet well enough
understood to permit a faithful simulation of real tumor
data. In assessing our methods, we must therefore rely
primarily on more indirect validation on real data.
There is no closely comparable method to ours of which
we are aware that we could use as a basis for comparison
and we therefore validate the results on the Navin et al.
data primarily by considering whether they are consistent
with prior knowledge about breast tumors. One could in
principle validate our results against recent work of Navin et
al. [27] using single-cell analysis of the subsections of Tumor
10 analyzed here. Navin’s phylogenetic approach, however,
leads to progression trees dominated by changes in overall
ploidy, which is not examined in our trees and precludes
any direct comparison. As noted previously, a majority of
the markers we ﬁnd correspond to some genes with known
cancer associations. These include well-characterized breast
cancer amplicons at 17q, 11q, and 20q [28–30]. The most
notable absence among well-known breast cancer markers
would be the 8p locus associated with the gene FGFR1. A
majority of the markers (16 of 27) include genes with some
annotatedrelationshipwithcancers,althoughonly7ofthose
(markers 1, 12, 13, 20, 22, 24, and 26) are annotated in
OMIM as speciﬁcally associated with breast cancers.
Of those markers lacking an annotated association with
breast cancers, many are in close proximity to and inherited
with breast-cancer-associated markers and might plausibly
be assumed to contain distinct portions of common ampli-
cons. Table 4 identiﬁes those proximal markers that are coin-
herited in the tree and likely reﬂect common amplicons. For
example, 17q is interpreted as three distinct markers (mark-
ers 19–21), and although only marker 20 contains genes with
an annotated breast cancer association (ERBB2/Her-2/neu,
STAT5, and GRB7), all are inherited together apparently
as a common amplicon. Similar explanations can account
for markers 2 on 1q, which is coinherited with marker 1
(MDM4); markers 10 and 11 on 8q, which are coinherited
with marker 12 (MYC); marker 25 and 27 on 20q, which are10 Journal of Biomedicine and Biotechnology
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Figure 4:Inferredcopynumberproﬁlesformixturecomponentsin
the vicinity of three markers from the data of Navin et al. [14]. The
x-axis of each ﬁgure corresponds to probes within a speciﬁc marker
region and the y-axis to copy number relative to the diploid control
inthatregionforeachcomponent.Thethinsolidlineineachplotat
value 1 shows the diploid threshold. Ampliﬁed components appear
in black and nonampliﬁed in grey. (a) Marker 1, corresponding to
theampliconat1q32.1-1q32.2.(b)Marker20,correspondingtothe
amplicon at 17q12-17q21.2.
coinheritedwithmarker26(ZNF217,CYP24A1,BCAS1,and
AURKA). In other cases, however, we observe coinherited
markers for which no speciﬁc explanation is available for
any of the markers. It is impossible to say purely from a
computational analysis whether these represent false pos-
itives, discoveries not annotated speciﬁcally in OMIM, or
even novel but signiﬁcant associations with breast cancer
progression.
Examining the phylogeny itself allows us to further
examine the possible biological signiﬁcance of the data and
Table 3: Ampliﬁed markers with probe boundaries and corre-
sponding cytogenetic coordinates for the data of Pollack et al. [25].
Marker
ID
Start probe
ID
End probe
ID Cytogenetic coordinate
1 1 37 1p36
2 136 272 1p34-1p22
3 330 649 1p13-1q44
4 671 790 2p24-2p13
5 1170 1210 3p25-3p21
6 1810 1889 5p15-5q11
7 2056 2229 5q23-6p21
8 2253 2331 6p21
9 2532 2865 7p22-7q36
10 2935 3106 8p12-8q24
11 3235 3264 9q22-9q31
12 3800 3926 11q12-11q14
13 4194 4255 12q12-12q14
14 4478 4522 13q22-14q11
15 4523 4566 14q11-14q12
16 4968 5367 16p13.3-17q11
17 5384 5448 17q11.2-17q21
18 5478 6056 17q21-19q13.4
19 6057 6230 20p13-20q13.33
20 6231 6312 21q11-21q22.3
Table 4: Marker regions ampliﬁed simultaneously during tumor
evolution. The table provides, for each such set of marker regions,
a unique identiﬁer, cytogenetic coordinates, and corresponding
speciﬁc edges or paths in the phylogenetic tree.
Coampliﬁed markers Phylogeny edges
18q21.32-18q22.2,18q21.2-18q21.3 12→ C2
1q32.1-1q32.2,1q44 11 →10
5q21.1-5q21.3, 5q22.3-5q23.1 11 → C6, 8 → C4
8q12.3-8q13.2,8q13.2-
8q13.3,8q21.11-8q24.3 11 →10
20q13.12,20q13.2-
20q13.32,20q13.33 10 → 9
7q31.2-7q31.31 9 → C3
15q25.2-15q25.3,15q26.3 8 → C4
17q11.2,17q12-17q21.2,17q21.33 11→ C6, 9 → 8
its concordance with current knowledge about breast cancer
progression. In this regard, it is helpful to interpret the tree
as a set of possible progression pathways from the healthy
root cell type (C0). As the tree implies, however, diﬀerent
progression pathways do not function in isolation but rather
may share some common features in early progression.
The ﬁrst internal node, Steiner node 12, is inferred to
be identical to the root, but diverges at the top level into
two pathways. The ﬁrst such progression pathway (C0 →Journal of Biomedicine and Biotechnology 11
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Figure 5: Inferred phylogenetic tree for the mixture components from the data of Navin et al. [14]. Nodes are labeled by component for
the six inferred components C1–C6 and the normal component C0. Internal nodes are inferred ancestral states (Steiner nodes) and are each
labeled by a unique identiﬁer (8–12). Tree edges are labeled with the markers inferred to be ampliﬁed across each. Markers inferred to be lost
along a given edge are shown in brackets and edges with no markers gained or lost are labeled “0.”
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Figure 6: Inferred phylogenetic tree for components derived from the data of Pollack et al. [25]. Nodes are labeled by component for the six
inferred components C1–C6. Internal nodes are inferred ancestral states (Steiner nodes) and are each labeled by a unique identiﬁer (7–9).
Tree edges are labeled with the markers inferred to be ampliﬁed across each. Markers inferred to be lost along a given edge are shown in
brackets and edges with no markers gained or lost are labeled “0.”12 Journal of Biomedicine and Biotechnology
12 → C2) describes a short terminal progression pathway
isolated from the rest of the tree. The progression pathway
is resolved only to a single step of mutation correspond-
ing to ampliﬁcation of 11q14.1–11q13.4, 18q21.32-18q22.2,
18q22.2–18q22.3. 11q is a known breast cancer amplicon
[29, 30] and harbors CCND1, which has been found
to be ampliﬁed in breast cancers [31]; FGF3 and FGF4,
which are known oncogenes [32]; and CTTN, which is
f r e q u e n t l yo v e r e x p r e s s e di nb r e a s tc a n c e r s[ 33]. The region
also contains other genes, such as NPAT, with functions in
cell cycle regulation that might be considered candidates
for an oncogenic function. 18q21.32-18q22.2 harbors the
oncogene BCL2, which is involved in the MYC pathway [34]
and TNFRSF11A, which is frequently expressed in late-stage
breast cancers [35, 36]. The marker also harbors several
SERPIN genes known to be tumor associated. 18q22.2–
18q22.3 does not carry any currently known cancer-related
genes but may be gained due to proximity to 18q21.32-
18q22.2 as part of a common amplicon. Together, these
abnormalities appear to deﬁne a distinct subclass of breast
tumor cells with early divergence from all other cell types.
Within the subbranch rooted at Steiner node 11, one
branch leads directly to a terminal node characterizing a sec-
ondprogressionpathway(C0 → 11 → C6).Thisprogression
pathway is characterized by ampliﬁcation of 5q21.1-5q21.3,
5q22.3-5q23.1, 11q23.3, 15q26.3, and 19q12 and is one
of two subtrees characterized by ampliﬁcation of 17q11.2,
17q12-17q21.2, and 17q21.33. The 17q region is a well-
established breast cancer hotspot [28, 30], including genes
ERBB2 (Her-2/neu), GRB7, and STAT5. 19q12 contains
CCNE1, an important prognostic marker for breast cancer
progression [37, 38]. CCNE1 ampliﬁcation has been specif-
ically associated with basal-like breast cancers [39], but has
been previously identiﬁed as coassociated with particularly
aggressive Her-2 positive breast tumors [40]. Our phylogeny
is consistent with the notion that 17q/19q coampliﬁcation
deﬁnes a distinct subtype of Her-2 positive tumors. Region
15q26.3 has no genes speciﬁcally noted to be breast-cancer
associated in OMIM, although ampliﬁcation of the locus
was identiﬁed as predictive of recurrence in systematic breast
cancers[41]andtheregioncontainsIGF1R,anantiapoptotic
g e n eb r o a d l ya m p l i ﬁ e di nc a n c e r s[ 42]. The biological
signiﬁcance of the 5q amplicon is not apparent. While
5q22.3-5q23.1 has several genes associated with cancers
(e.g., ATG12, TNFAIP8, SEMA6A, which are associated with
lung cancer), they are predominantly tumor suppressors.
Likewise, there is no obvious relevance to the 15q amplicon,
although it is close to other known 15q markers.
The next major division in the tree corresponds to the
branch from Steiner nodes 11 to 10, characterized by gains in
1q32.1-1q32.2, 1q44, 8q12.1, 8q12.3-8q13.2, 8q13.2-8q13.3,
and 8q21.11-8q24.3. Both 1q and 8q are rich in tumor-
associatedgenes.1q32.1includesthebreastcancerassociated
gene MDM4, a putative oncogene involved in apoptosis
regulation of p53 activity [43], in addition to various
genesassociatedwithcancersmoregenerally.8q21.11-8q24.3
includes the MYC locus, another well known breast cancer
amplicon [30]. We can suggest, then, that the 11 → 10
branch corresponds to a speciﬁc subset of progression path-
ways characterized by MYC ampliﬁcation and suppression of
apoptosis.
A third progression pathway can be identiﬁed within this
branch through progression into C1 (C0 → 12 → 11 →
10 → C1). The ﬁnal step on this pathway is characterized
by ampliﬁcations on 12p11.22-12p11.21 and 19q12. 19q12
is the locus of CCNE1 suggesting a generic connection to
cell cycle control on this pathway. 12p11.22-12p11.21 has no
known cancer-related genes but carries the apoptosis-related
gene DNM1L and the telomerase-related gene DDX11
[44].
Further progression pathways diverge from Steiner node
10 through Steiner node 9 with gains on 5p15.33-5p14.2,
20q13.12,20q13.2-20q13.32,and20q13.33.The5pamplicon
contains two genes with known cancer associations, CDH18
[45]a n dP A P D 7[ 46], although neither appears to have a
known role in breast cancers speciﬁcally. 20q13.2-20q13.32
contains several genes associated with breast cancers, includ-
ing ZNF217, CYP24A1, BCAS1, and AURKA [30], making it
diﬃcult to ascribe a particular mechanism to this branch.
Within the Steiner node 9 subtree, we can characterize a
fourth progression pathway terminating in C3 (C0 → 11 →
10 → 9 → C3). The ﬁnal step on this progression pathway
corresponds to gains on 2p12, 3q25.1-3q25.2, and 7q31.31-
7q31.32. The 7q31.32 marker contains the WNT2 gene
associated with many cancer types, including breast cancer
[47]. 7q31.31 has no known cancer-related genes and is
perhaps gained due to its proximity to 7q31.2. 3q25.1-3q25.2
h a sb e e np r e v i o u s l yd e t e c t e da sa na m p l i c o ni nf r a c t i o no f
breast cancers [48], although we can oﬀer no mechanistic
explanation for its presence. We are not aware of any prior
suggestion of an association between 2p12 and cancers.
The remaining two terminal nodes of the tree, C4 and
C5, appear likely to represent two steps on a common pro-
gression pathway. Both branchs from Steiner node 9 through
8 by acquisition of 17q11.2, 17q12-17q21.2, 17q21.33 (the
Her-2 locus) along with 11q13.2. This subtree might thus
be characterized primarily as a second Her-2 positive pro-
gressiongroupassociatedwithgainofCCND1,distinctfrom
the Her-2 positive progression group terminating at C6 and
associated with gain of CCNE1. C5 branches from Steiner
node 8 with no changes, indicating a single progression
pathway corresponding to C0 → 11 → 10 → 9 → C5 →
C4. The ﬁnal step in this pathway is then characterized
by a series of ampliﬁcations on 5q21.1, 5q22.3, 12p11.22,
15q25.2, 15q26.3, and loss of 8q12.1. We would not expect
loss of a previously gained marker, and can suggest that this
apparent loss might be better explained as a miscall of the
state of that marker. Most of these loci have no annotated
associationwithanycancers,withtheonlyspeciﬁcannotated
breast cancer association being to 11q13.2, described above.
This lack of associations may again represent false positive
inferences speciﬁcally associated with this component. We
can suggest, however, that such markers might be have been
missed if they are speciﬁc only to late progression of one
subtype of Her-2 positive breast tumor. Summarizing acrossJournal of Biomedicine and Biotechnology 13
the tree, we can note that there is clear support in the prior
literature for many of the speciﬁc markers, although there is
little evidence one way or the other supporting the speciﬁc
sequences of mutations suggested by our phylogeny analysis.
Nonetheless, these pathways make several novel predictions
that may warrant further investigation. Chief among these
would be the identiﬁcation of two apparently distinct
pathways to Her-2/neu ampliﬁcation that separate relatively
early in progression and exhibit distinct sets of co-occurring
ampliﬁcations.
The tree suggests several distinct patterns of coampli-
ﬁcation that may be useful in identifying or classifying
novel subtypes, particularly with respect to Her-2 ampli-
fying tumors. Of particular interest are the observation
of two distinct Her-2 amplifying subtrees, one showing
coampliﬁcation with CCND1 and c-myc and the other with
CCNE1. Loden et al. have previously reported separate
Cyclin-D ampliﬁed and Cyclin-E ampliﬁed subgroups of
breast cancer following separate pathways of oncogenesis,
with Her-2/neu overexpression and c-myc ampliﬁcation
accompanying both subgroups. Coampliﬁcation of Her-2,
CCND1, and c-myc is supported by additional literature,
with this particular coampliﬁcation associated with later or
moreadvancedstagesofbreastcancer[40,49,50].Janockoet
al. [49], however, do suggest that c-myc ampliﬁcation should
occur late in this sequence, a ﬁnding not supported by our
phylogeny.Othermorerecentworkhassupportedtheideaof
Her-2 and CCNE1 coampliﬁcation in breast cancers [51, 52]
withScaltritietal.speciﬁcallysuggestingthiscoampliﬁcation
as a possible mechanism for Herceptin resistance in Her+
breast tumors. Other patterns of complication are apparent
in the tree although not to our knowledge supported by
prior literature or any obvious functional interpretation, for
example,theobservationofcoampliﬁcationoflocion5qand
15q in both Her-2 amplifying subtrees.
AdditionalanalysisofthePollacketal.[25]provideslittle
additional insight into breast tumor development, although
it does provide some independent validation of our method.
While the lower resolution of those data prevents an analysis
of speciﬁc ampliﬁed breast tumor genes comparable to
that done with the Navin et al. data, we can nonetheless
observe that the method is eﬀective at picking out those
amplicons noted by the authors of that study. Furthermore,
the additional markers it detects beyond those four include
several of those also inferred to be important progression
markers on the Navin et al. data and supported by extensive
priorliterature,mostprominentlythelociofHer-2,CCND1,
andCCNE1.Theseresultsshowthatthemethodcanrobustly
ﬁnd at least some prominent known tumor markers across
two distinct sets of tumor samples using very diﬀerent
aCGH platforms and distinct unmixing methods. The tree
itself provides no obvious new insights into breast tumor
progression, as the method detected only four components
that were actually distinct at the level of assigned markers,
with three components determined to be ampliﬁed at
all markers. Furthermore, all identiﬁed components were
inferred to lie along a single progression pathway. It is
notable that the tree implies ampliﬁcation of most of the
identiﬁed markers in a majority of components, perhaps
because of the late clinical stages of the tumor samples and
the presence of cell lines that would provide reasonably
homogeneous representations of advanced states of breast
tumor progression.
4. Conclusion
In this paper, we have developed a computational pipeline
for tumor phylogeny inference from genome-scale proﬁles of
tumorstate,speciﬁcallytotestthefeasibilityofusingcompu-
tationalunmixingmethodstocircumventtheproblemofcell
type heterogeneity in tumor phylogeny in-ference. We have
developed a set of statistical tests to allow us to analyze com-
putationally inferred mixture components—representing
inferred proﬁles of well-populated cell types from which
heterogeneous tumor samples can be explained—to identify
phylogenetic markers, assign them to speciﬁc inferred cell
types, and use them in phylogenetic inference of tumor
progression. We have demonstrated the approach with spe-
ciﬁc application to aCGH DNA copy number data, applied
to a breast cancer data set [14], showing that the method
is eﬀective at locating biologically meaningful markers of
tumor progression and assembling a biologically plausible
model of breast tumor progression pathways. The inferred
progression pathways provide several novel suggestions
about possible steps in tumor evolution and key molecular
abnormalities associated with progression. These inferences
may provide useful guidance into the basic biology of tumor
development as well as suggestions of possible targets for
future diagnostics and therapeutics. Further application to
a secondary lower-resolution breast tumor data set [25]a n d
to a series of simulated aCGH data sets provides additional
evidence for the eﬀectiveness of the method at identifying
markers of tumor progression, grouping them correctly into
well-represented progression states, and accurately placing
these states in phylogenetic trees.
Validation remains a challenge for tumor phylogeny
inference, as there is no alternative method by which we can
determine progression pathways with certainty for any real
tumor data set. Simulated data can lend some conﬁdence
that the method works eﬀectively relative to a model of the
real data, as has been done here, but real tumor progression
mechanisms are likely to be far more complex than our
simulation models can capture. Comparison to single-cell
approaches like FISH [13, 49, 53] and single-cell sequencing
eﬀorts [27] can help to verify the pure cell states determined
by the unmixing within a single sample and potentially
validate some ancestral states predicted by the phylogenetic
inference. FISH data provides only a few markers per cell,
making it infeasible for a comprehensive validation of the
results of our method, but could be used prospectively on
targetedmarkersselectedfromaninferredphylogeny.Single-
cell sequencing approaches could in principle eventually
overcomethislimitationgivensuﬃcientvolumesandquality
of data. Other sources of data in which more information is
available about the true pathways of progression might also
be useful. While we know of no such data currently available,
one might in principle construct such a data set by, for14 Journal of Biomedicine and Biotechnology
example, studying discrete passages of cell lines or through
the use of animal models in which one can monitor tumor
development and progression over time. While gathering
such a data set would be beyond the scope of the present
work, it could in principle provide a basis for a more
thorough future assessment of the accuracy of the pipeline
implemented here or other methods for the problem of
tumor phylogeny inference.
While this pilot study was intended to establish the
feasibility of an unmixing approach to tumor phylogenetics,
there are many ways by which the work might be advanced
in the future. It will be important to further establish the
reproducibility of the speciﬁc markers and phylogenetic
pathways in additional breast tumor datasets. Novel markers
found to be robustly predictive of particular progression
pathways will ultimately need to be experimentally veriﬁed.
In addition, it will be important to establish that the
approach is applicable to other forms of tumors. Each of
the individual steps of analysis also might beneﬁt from
improvement. The approach developed here depends on use
of an unmixing method for identifying progression states,
a problem which itself might beneﬁt from improvements
in the model and algorithms to more precisely ﬁt the
kind of sparse noisy data characteristic of tumor data sets.
Adapting the methods to more reliable data types, such as
next generation sequencing data, may also prove valuable in
that regard. The results on marker detection suggest there is
room for improvement in more precisely determining the
ﬁne-scale structure of speciﬁc amplicons, especially when
contiguous regions show distinct patterns of ampliﬁcation
acrosscomponents. Likewise,therewouldappeartoberoom
for improvement in better discriminating between normal
and slightly elevated copy numbers. It is a weakness of the
general approach that, because the unmixing models must
work in linear rather than log space, they have diﬃculty
distinguishingtherelativelysmalllinearchangebetweennor-
mal and deleted regions. Improving sensitivity for deletions,
or for subtler variations among ampliﬁcation levels, may
provide additional data for phylogeny construction. Finally,
the phylogeny construction itself used a standard parsimony
method not speciﬁcally tailored to tumor progression. This
parsimonymodelhasadvantagesinnotrequiringparameters
for which there is currently no empirical basis and in
allowing us to test for unexpected behavior, such as loss
of previously ampliﬁed regions, that can help to validate
the method. Nonetheless, there is now suﬃcient data that
one might in principle learn more sophisticated probabilistic
models of cancer progression or of the behavior of particular
amplicons and build these models into the phylogeny
inference.
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